Liver steatosis, cardiac and renal fibrosis, and hypertension in overweight rats: Angiotensin-(3-4)-sensitive hepatocardiorenal syndrome
- PMID: 35392380
- PMCID: PMC8980470
- DOI: 10.1016/j.metop.2022.100176
Liver steatosis, cardiac and renal fibrosis, and hypertension in overweight rats: Angiotensin-(3-4)-sensitive hepatocardiorenal syndrome
Abstract
Overweight/obesity is a growing pandemic that affects many organs and tissues. We have investigated whether a high-lipid diet provokes an imbalance between type 1 and type 2 angiotensin II (Ang II) receptors signaling, leading to liver alterations associated with cardiovascular and kidney disturbances. Chronic administration of a high-lipid diet can provoke hepatocardiorenal syndrome resulting from activation of the Ang II→type 1 receptor axis, which is entirely counteracted by Ang-(3-4), the allosteric enhancer of the Ang II→type 2 receptor pathway.
Keywords: Arterial hypertension; Cardiac and renal fibrosis; Hepatocardiorenal syndrome; Hyperlipidic diet; Non-alcoholic liver steatosis; Overweight rats.
© 2022 The Authors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Histone Deacetylase Activity and the Renin-Angiotensin-Aldosterone System: Key Elements in Cardiorenal Alterations Provoked by Chronic Malnutrition in Male Adult Rats.Cell Physiol Biochem. 2020 Nov 18;54(6):1143-1162. doi: 10.33594/000000306. Cell Physiol Biochem. 2020. PMID: 33201644
-
Downregulation of the ACE2/Ang-(1-7)/Mas axis in transgenic mice overexpressing GH.J Endocrinol. 2014 Apr 22;221(2):215-27. doi: 10.1530/JOE-13-0497. Print 2014 May. J Endocrinol. 2014. PMID: 24756097 Free PMC article.
-
Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism.J Hypertens Suppl. 1997 Dec;15(6):S13-9. J Hypertens Suppl. 1997. PMID: 9493122
-
Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.Curr Hypertens Rep. 2017 Feb;19(2):16. doi: 10.1007/s11906-017-0708-3. Curr Hypertens Rep. 2017. PMID: 28233239 Free PMC article. Review.
-
The role of renin-angiotensin system modulation on treatment and prevention of liver diseases.Peptides. 2014 Dec;62:189-96. doi: 10.1016/j.peptides.2014.10.005. Peptides. 2014. PMID: 25453980 Review.
Cited by
-
Counter-regulatory RAS peptides: new therapy targets for inflammation and fibrotic diseases?Front Pharmacol. 2024 Apr 10;15:1377113. doi: 10.3389/fphar.2024.1377113. eCollection 2024. Front Pharmacol. 2024. PMID: 38666016 Free PMC article. Review.
-
Editorial: Special issue: Non-alcoholic fatty liver disease: From molecular basis to therapeutic advances.Metabol Open. 2023 Jan 13;17:100229. doi: 10.1016/j.metop.2023.100229. eCollection 2023 Mar. Metabol Open. 2023. PMID: 36686606 Free PMC article. No abstract available.
References
-
- Luzes R., Crisóstomo T., Silva P.A., Iack R., de Abreu V.G., Francischetti E.A., Vieyra A. Angiotensin-(3–4) normalizes blood pressure, decreases Na+ and energy intake, but preserves urinary Na+ excretion in overweight hypertensive rats. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2021;1867:166012. doi: 10.1016/j.bbadis.2020.166012. - DOI - PubMed
-
- Dias J., Axelband F., Lara L.S., Muzi-Filho H., Vieyra A. Is angiotensin-(3–4) (Val-Tyr), the shortest angiotensin II-derived peptide, opening new vistas on the renin-angiotensin system? J Renin-Angiotensin-Aldosterone Syst JRAAS. 2017;18 doi: 10.1177/1470320316689338. 1470320316689338. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous